Prostate Cancer
AMG509 20230239: A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
- Details
ClinicalTrials.gov ID:
NCT07213674
Diagnosis Type:
NA
USOR Number:
- Address
,
P: